G

Galderma

Independent dermatology company delivering skincare therapies

Plant Engineering & Operations Manager

Full-Time
No salary listed
Senior, Expert
Bachelor's, Master's
Raleigh, NC, USA+1 moreMore locations: Philadelphia, PA, USA
In PersonOccasional travel may be required.
Facilities OperationsFacilities Management
No H1B Sponsorship

About the job

Requirements
  • Bachelor’s or Master’s degree in Engineering, preferably Mechanical, Electrical, Process, Automation, Chemical, Industrial, Utilities, Building Services, or a related technical discipline.
  • 8–10 years of related experience in Plant Engineering, Utilities, Facilities, Maintenance, Engineering Operations, or a comparable regulated manufacturing environment.
  • Fluent written and spoken English and the site local language are required.
  • Experience with utility systems, facility systems, maintenance programs, shutdown planning, reliability programs, site services, external contractors, project handover, OPEX/CAPEX planning, and cross-functional stakeholder management.
  • Plant engineering, utilities, facilities, and infrastructure technical expertise.
  • GMP/cGxP, quality systems, validation/qualification, and inspection readiness knowledge.
  • Integrated Facilities Management, including hard and soft services.
  • CAPEX support, project sponsorship, and business case development.
  • OPEX/CAPEX budget planning.
  • Automation/building management system interface knowledge and reporting for energy and water KPIs.
  • Operational leadership in regulated environments.
  • Strong stakeholder management and influencing capability.
  • Strong risk-based decision-making.
  • Supplier and contractor governance.
  • Ability to advise the business on facility and utility limitations.
  • People leadership, including coaching, feedback, and recruitment.
  • The ability to perform standard office activities, including extended periods of computer use and participation in virtual and in-person meetings.
  • Eligibility to work in the United States is required.
Responsibilities
  • Lead the local Plant Engineering and Operations function to ensure safe, compliant, reliable, and efficient site operations.
  • Provide engineering leadership for manufacturing operations across Consumer Cosmetics, Rx/OTC, and Injectable Aesthetics areas.
  • Ensure engineering services support production continuity, product quality, EHS requirements, and regulatory compliance.
  • Act as the primary site engineering interface for Operations, Quality, EHS, Technical Services, Validation, Procurement, and Global Engineering.
  • Lead site engineering governance forums, performance reviews, issue escalation, and improvement planning.
  • Translate global plant engineering strategy, standards, and performance expectations into local site execution plans.
  • Ensure the reliable and compliant operation of site utility and infrastructure systems, including water, compressed air, steam, chilled water, electrical infrastructure, HVAC interfaces, waste treatment, facilities, buildings, roads, drainage, roofs, civil assets, fire protection, and site services.
  • Give input to maintenance strategy execution for site utilities, facilities, and infrastructure assets.
  • Liaise with Maintenance and Reliability teams to maintain preventive, predictive, and corrective maintenance programs.
  • Drive asset reliability, uptime, and lifecycle performance using data-led maintenance and reliability tools.
  • Monitor and improve asset availability, maintenance compliance, breakdown frequency, recurring failures, backlog, schedule adherence, and cost performance.
  • Lead root cause analysis for significant equipment, utility, and infrastructure failures.
  • Maintain asset registers, equipment hierarchies, criticality assessments, spare-parts strategies, and lifecycle replacement plans.
  • Support site capital plans for asset renewal, reliability improvement, compliance remediation, and capacity expansion.
  • Ensure engineering operations comply with applicable GMP, GDP, GEP, EHS, local regulatory, and company requirements.
  • Maintain engineering systems in an inspection-ready state.
  • Ensure documentation, maintenance records, calibration interfaces, change controls, deviations, CAPAs, and validation support are completed in accordance with quality requirements.
  • Partner with Quality and Validation teams to keep qualified utilities and systems in a validated state.
  • Support internal and external audits, regulatory inspections, and customer audits as the engineering subject matter expert.
  • Ensure engineering changes are assessed for quality, safety, validation, and operational impact.
  • Lead the site Integrated Facilities Management model, including governance of outsourced service providers and internal facilities resources.
  • Manage service delivery across building maintenance, cleaning, landscaping, security interfaces, waste management, pest control, workplace services, and technical facilities operations.
  • Ensure Integrated Facilities Management suppliers meet service levels, compliance obligations, safety requirements, cost targets, and continuous-improvement expectations.
  • Own supplier performance reviews, contract governance, issue escalation, and improvement plans.
  • Partner with Procurement and Legal on Integrated Facilities Management contract scope, renewals, commercial performance, and supplier risk management.
  • Ensure engineering, maintenance, utilities, and facilities activities comply with EHS standards.
  • Lead engineering risk assessments for utilities, infrastructure, maintenance activities, and contractor works.
  • Drive energy efficiency, water stewardship, waste reduction, emissions reduction, and sustainability initiatives across site engineering operations.
  • Support site decarbonization, energy optimization, and resource-efficiency targets.
  • Ensure statutory inspections, permits, pressure systems, electrical safety, confined-space controls, contractor safety, and environmental systems are managed effectively.
  • Own or support business-continuity planning for critical utilities and infrastructure.
  • Ensure emergency-response plans are in place for major utility failures, infrastructure incidents, and site-service disruptions.
  • Maintain risk registers with insurer actions followed and aligned with business-continuity plans.
  • Provide site engineering input into capital-investment planning, project prioritization, and engineering-project execution.
  • Support project delivery for utility upgrades, infrastructure improvements, compliance remediation, capacity expansion, and asset replacement.
  • Ensure local operational requirements are captured in project scopes, user requirements, design reviews, commissioning, qualification, and handover.
  • Partner with Global Engineering and project teams to ensure projects meet site needs and are operationally sustainable.
  • Ensure smooth transition from project delivery into routine operation, including maintenance plans, spare parts, training, documentation, qualification, and asset master data.
  • Lead or support technical change controls associated with utilities, facilities, infrastructure, and equipment modifications.
  • Lead, coach, and develop the local engineering operations team.
  • Build capability in maintenance excellence, reliability, utilities operation, GMP compliance, EHS, troubleshooting, and contractor management.
  • Set clear objectives, manage performance, and create development plans for team members.
  • Ensure adequate technical capability, succession planning, and resource planning to support site needs.
  • Promote cross-functional teamwork with Operations, Quality, EHS, Technical Services, Validation, Finance, Procurement, and Global Engineering.
Desired Qualifications
  • Minimum 5 years of leadership, supervisory, or managerial experience is preferred.
  • Previous experience within cGxP, pharmaceutical, medical aesthetics, consumer healthcare, cosmetics, sterile/injectable manufacturing, or another regulated industry is highly recommended.
  • Occasional travel may be required.

About the company

Dermatology-focused medicines and skincare products are Galderma’s core business, including prescription therapies, over-the-counter skincare, and injectable aesthetics. It combines pharmaceutical R&D with consumer skin insights to develop treatments that address skin conditions, improve appearance, and support overall skin health. Unlike many peers, Galderma operates as an independent, publicly traded dermatology specialist with a long history in skin science, spanning prescription, OTC, and aesthetic segments. Its goal is to be a global leader in science-based solutions for skin conditions, growing across therapeutic dermatology, injectables, and skincare worldwide.

Company Size

1,001-5,000

Company Stage

Private

Total Funding

$5.7B

Headquarters

Lausanne, Switzerland

Founded

1981

Get referred to Galderma

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales hit $3.134 billion, up 24.6%, and guidance rose to 19-21%.
  • Galderma opened Miami headquarters in August 2026, targeting 200 staff and stronger U.S. selling.
  • The $650 million U.S. manufacturing buildout through 2030 supports supply and tariff resilience.

What critics are saying

  • FDA's July 1, 2026 Relfydess CRL pushes U.S. launch toward 2027.
  • AbbVie's Allergan Aesthetics still dominates Botox and Juvéderm, keeping Galderma behind.
  • Nemluvio and Relfydess depend on execution in the U.S.; another regulatory miss crushes momentum.

What makes Galderma unique

  • Relfydess, approved in 33 markets by July 2026, gives Galderma a proprietary neuromodulator.
  • Galderma spans Cetaphil, Restylane, Sculptra, Nemluvio, and Dysport across dermatology categories.
  • The September 21, 2026 SMI inclusion validates its scale and Swiss capital-market credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Aesthetics Journal
Oct 19th, 2026
The latest appointments within Medical aesthetics.

The latest appointments within Medical aesthetics. * October 19, 2026 Aesthetics rounds up the latest company appointments announced within the aesthetics community Pharmaceutical company Galderma has announced the appointment of Juan Rodrigo Betancur as general manager for UK and Ireland. Betancur commented, "I'm delighted to be joining Galderma UK and Ireland at such an exciting time for aesthetics. Patient expectations are evolving towards more natural, personalised and holistic approaches to ageing and skin quality. Galderma is uniquely positioned to shape this evolution through a comprehensive portfolio grounded in science and innovation. My ambition is to grow the category and strengthen Galderma's role as a trusted partner to healthcare professionals and patients, with science, education and innovation at the heart of what we do." Laser manufacturer Candela Medical has appointed Victoria Worship as assistant vice president for UK, Ireland and Iberia. The company shares that in her new role, Worship will oversee sales operations and lead the... Subscriber content To read this post in full you need an Aesthetics Journal subscription. Choose the plan that fits your practice - every paid plan includes the complete peer-reviewed clinical library and CPD-accredited learning. Quick links: October 19, 2026

Yahoo Finance
Oct 14th, 2026
Galderma to buy ZO Skin Health from Blackstone for $1.5B, Reuters reports

Swiss skincare group Galderma has agreed to buy medical-grade skincare company ZO Skin Health from Blackstone for about $1.5 billion, Reuters reported, citing two people familiar with the matter. An announcement could come in the coming days. The deal would strengthen Galderma's presence in the US, where competition is growing for physician-distributed skincare brands backed by clinical research. Galderma opened its US and Latin America headquarters in Miami in August. L'Oréal holds a 20% stake in Galderma, which also owns Cetaphil and Alastin Skincare. Its products include prescription acne treatments, the Dysport neurotoxin, and Restylane dermal fillers.

Archyde
Oct 13th, 2026
Galderma agrees to buy ZO Skin Health, sources say.

Galderma agrees to buy ZO Skin Health, sources say. Discover more News website advertising Swiss dermatology conglomerate Galderma (GALD.S) has agreed to acquire medical-grade skincare company ZO Skin Health for approximately $1.5 billion, according to two people familiar with the matter. The transaction expands Galderma's footprint in the U.S. physician-distributed skincare market. Strategic financial takeaways. * Valuation Target: The acquisition agreement values ZO Skin Health at approximately $1.5 billion. * Sellers and Advisors: Investment firm Blackstone (BX.N) previously explored a sale through advisors Citigroup (C.N) and Raymond James (RJF.N). * Ownership Structure: Beauty conglomerate L'Oréal (OREP.PA) holds a 20% stake in Galderma. Expanding the U.S. Medical skincare portfolio. Strategic buyers continue to prioritize clinically backed, physician-distributed skincare brands due to steady consumer demand and high barriers to entry compared to over-the-counter alternatives. For Galderma, this acquisition adds a prominent professional-grade portfolio to an existing lineup that includes Cetaphil, Alastin Skincare, Differin Epiduo acne gel, Dysport, and Restylane. Established in 1981, Galderma recently reinforced its regional footprint by opening a U.S. and Latin America headquarters in Miami in August. ZO Skin Health was founded in 2007 by dermatologist Zein Obagi. The brand distributes cleansers, serums, exfoliators, and toners through physicians and licensed skincare professionals. Blackstone (BX.N) acquired the company in 2020 through its tactical opportunities fund. Last month, Reuters reported that Blackstone was evaluating exit options with financial advisers Citigroup and Raymond James. Discover more Freelance journalism platform Learn Engineering Transaction timeline and market response. | Event / Milestone | Details | Key Entities | | Founding of ZO | | Established in 2007 by dermatologist Zein Obagi | ZO Skin Health | | PE Acquisition | | Acquired via tactical opportunities fund in 2020 | Discover more Taste Euro Foods Buy Maps Explore History Business news analysis Investigative journalism courses Journalism ethics training Get Health Tips health | Blackstone (BX.N) | | Sale Exploration | Evaluated sale options with financial advisors | Citigroup (C.N), Raymond James (RJF.N) | | Acquisition Agreement | | Agreed to buy ZO Skin Health for ~$1.5 billion | | Galderma (GALD.S) | The formal announcement of the transaction is expected in the coming days, according to sources familiar with the discussions. Representatives for Galderma and ZO Skin Health did not immediately respond to requests for comment outside regular business hours. Blackstone declined to comment on Tuesday. Discover more News subscription service Digital news archive Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice. More on this Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.

MarketScreener
Oct 13th, 2026
Galderma agrees to buy ZO Skin Health for around $1.5 billion, sources say.

Galderma agrees to buy ZO Skin Health for around $1.5 billion, sources say. Published on 10/13/2026 at 07:14 pm EDT - Modified on 10/13/2026 at 07:19 pm EDT NEW YORK, Oct 13 (Reuters) - Swiss skincare conglomerate Galderma has agreed to buy medical-grade skincare company ZO Skin Health for around $1.5 billion, according to two people familiar with the matter. A deal could be announced in the coming days, the people said. ZO and Galderma, which were contacted outside regular business hours, did not immediately respond to requests for comment. ZO's owner, investment firm Blackstone, was exploring a sale of the company with investment banks Citigroup and Raymond James, Reuters reported last month. Blackstone declined to comment on Tuesday. The move by dermatology company Galderma, in which beauty giant L'Oréal owns a 20% stake, will expand its presence in the US market. In August, the company opened a US and Latin America headquarters in Miami. Established in 1981, Galderma also owns skincare brands Cetaphil and Alastin Skincare, Differin Epiduo acne gel, injectable neurotoxin Dysport, and dermal filler brand Restylane. Many strategic buyers are prioritizing clinically backed, physician-distributed skincare brands like ZO because of their efficacy and steadier demand versus over-the-counter products. Dermatologist Zein Obagi founded ZO in 2007. ZO sells skincare products including cleansers, serums, exfoliators and toners that are distributed by physicians and skincare professionals. Blackstone acquired ZO through its tactical opportunities fund in 2020. (Reporting by Abigail Summerville in New York; Editing by Echo Wang in New York and Jamie Freed) By Abigail Summerville (C) Reuters - 2026

MarketScreener
Oct 8th, 2026
Galderma presents new three-year Nemluvio data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older.

Galderma presents new three-year Nemluvio data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older. Published on 10/08/2026 at 07:20 am EDT S&P Capital IQ Galderma announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Clinical Dermatology Conference, taking place from October 08-11 in Las Vegas, United States. This includes a new post-hoc analysis from the ARCADIA LTE study showing that in adults and adolescents aged 12 and older who achieved an early response at Week 16 in the ARCADIA trial, Nemluvio achieved deep and lasting skin lesion and itch responses for up to three years. New post-hoc data from the ongoing ARCADIA LTE study showed that adults and adolescents aged =12 years with moderate-to-severe atopic dermatitis who achieved an early clinical response with Nemluvio in the ARCADIA trials, were able to maintain deep and lasting improvements in both skin lesions and itch response through Week 152. The analysis evaluated 295 patients who achieved a clinical response at Week 16 and continued treatment during the maintenance and LTE phases of the study. Deep skin clearance was assessed by the proportion of participants achieving an IGA score of 0 or 1, and those with a more than 90% or 100% improvement from the initial baseline in the EASI score. Among these early responders at one year (Week 56), 77% achieved clear skin or at least a 90% improvement in disease severity. This was maintained up to Week 152, where 76% achieved clear (IGA 0) or almost clear skin (IGA 1), and 80% achieved at least a 90% improvement in disease severity (EASI-90) and 50% achieved complete skin clearance (EASI-100). In addition, at Week 152, 80% achieved an itch-free or nearly itch-free state. Nemluvio was well tolerated, with no new safety signals. The data are consistent with the previously collected safety and efficacy data regarding Nemluvio in adults and adolescents with moderate-to-severe atopic dermatitis. These findings further strengthen the growing body of evidence supporting the long-term efficacy of Nemluvio and its potential to deliver lasting disease control across key symptoms of atopic dermatitis. A separate pre-specified interim analysis of the overall ARCADIA LTE population assessed the long-term safety and efficacy of Nemluvio in 1,903 adults and adolescents aged =12 years with moderate-to-severe atopic dermatitis. At Week 152, Nemluvio was well-tolerated and associated with sustained efficacy, including improvements in skin lesions, itch, sleep disturbance and quality of life. Based on observed case analyses: Up to 91% of patients achieved at least 75% improvement in eczema severity (EASI-75), and up to 75% achieved at least 90% improvement in eczema severity (EASI-90); Up to 67% of patients achieved clear or almost clear skin (IGA 0/1); Up to 88% of patients achieved clinically meaningful itch relief and up to 73% achieved an itch-free or nearly itch-free state; Up to 92% of patients achieved clinically meaningful improvements in dermatology-related quality of life. The safety profile of Nemluvio remained consistent with previous findings through three years of treatment, with no new safety signals identified compared to previous long-term extension study interim analyses. Galderma will also present clinical results from a phase II study designed to assess the pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis. Results showed that nemolizumab pediatric doses were associated with similar pharmacokinetic exposure compared to adults and adolescents, and were well tolerated and effective in children, with clinically meaningful reductions in skin lesions and itch through Week 16 and sustained up to Week 52. A separate descriptive analysis from the OLYMPIA LTE study showed that Nemluvio also delivered sustained and clinically meaningful improvements across multiple dimensions of prurigo nodularis burden through Week 148, including itch, pain, sleep disturbance, quality of life and overall health status. At Week 48, out of 508 enrolled patients: More than 85% of patients achieved clinically meaningful itch improvement, with about three-quarters of patients achieving an itch-free or nearly itch-free state; 60% reported no prurigo nodularis-associated pain; 85% achieved clinically meaningful improvements in sleep disturbance; 91% experienced clinically meaningful improvements in quality of life; The safety profile of Nemluvio remained consistent with previous findings through three years of treatment, with no new safety signals identified compared to previous long-term extension study interim analyses. Nemolizumab is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31? a neuroimmune cytokine that drives itch and is involved in inflammation, epidermal dysregulation and fibrosis in both atopic dermatitis and prurigo nodularis. (C) S&P Capital IQ - 2026